Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.3%

30 terminated/withdrawn out of 363 trials

Success Rate

87.9%

+1.4% vs industry average

Late-Stage Pipeline

6 trials in Phase 3/4

Results Transparency

30%

66 of 218 completed trials have results

Key Signals

68 recruiting66 with results12 terminated18 withdrawn

Enrollment Performance

Analytics

N/A

180(57.9%)

Phase 2

63(20.3%)

Phase 1

51(16.4%)

Early Phase 1

11(3.5%)

Phase 4

5(1.6%)

Phase 3

1(0.3%)

311Total

N/A(180)

Phase 2(63)

Phase 1(51)

Early Phase 1(11)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (363)

Showing 20 of 363 trials

NCT06964737Phase 1Recruiting

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Role: lead

NCT06949943Not ApplicableRecruiting

Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery

Role: lead

NCT04713618Active Not Recruiting

Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy

Role: lead

NCT06950008Not ApplicableActive Not Recruiting

A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer

Role: lead

NCT07564648Not ApplicableNot Yet Recruiting

Impact of Novel vs. Usual Brand Menthol Cigarettes on Abuse Liability

Role: lead

NCT07529483Phase 2Not Yet Recruiting

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms

Role: lead

NCT05730439Early Phase 1Completed

Examining the Impact of Nicotine Pouches in Rural Ohio and Ohio Appalachia

Role: lead

NCT07447700Not ApplicableRecruiting

A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer

Role: lead

NCT06315881Phase 2Recruiting

Informing Oral Nicotine Pouch Regulations to Promote Public Health

Role: lead

NCT03878199Phase 1Terminated

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Role: lead

NCT03691350Early Phase 1Completed

Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs

Role: lead

NCT06448351Not ApplicableRecruiting

Manipulating E-Cigarette Nicotine to Promote Public Health

Role: lead

NCT06741072Phase 1Suspended

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Role: lead

NCT06424522Not ApplicableRecruiting

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

Role: lead

NCT07216534Not ApplicableRecruiting

Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants

Role: lead

NCT07407647Phase 2Recruiting

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Role: lead

NCT03113136Not ApplicableCompleted

Examination of Low Wattage and High Wattage E-Cigarettes

Role: lead

NCT07166419Phase 1Recruiting

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Role: lead

NCT02259218Completed

Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy

Role: lead

NCT05106374Completed

Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer

Role: lead